Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary W. Pace Purchases 15,000 Shares

Key Points

• Gary W. Pace, a director at Cardiff Oncology, Inc., purchased 15,000 shares at an average price of $2.45, increasing his total ownership to 1,345,676 shares.
• Cardiff Oncology reported an EPS of ($0.21) for the last quarter, missing analyst expectations by two cents, while revenues slightly exceeded forecasts at $0.12 million.
• Analysts have a Moderate Buy rating on Cardiff Oncology, with prices targets as high as $19.00 from recent reports, indicating optimism about the company's potential growth.

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) Director Gary W. Pace acquired 15,000 shares of the stock in a transaction dated Wednesday, July 30th. The shares were purchased at an average cost of $2.45 per share, with a total value of $36,750.00. Following the completion of the purchase, the director owned 1,345,676 shares of the company's stock, valued at approximately $3,296,906.20. The trade was a 1.13% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Cardiff Oncology Stock Performance

Shares of Cardiff Oncology stock traded down $0.09 on Monday, hitting $2.56. 1,155,983 shares of the company's stock were exchanged, compared to its average volume of 1,434,309. The company has a 50-day simple moving average of $3.59 and a 200-day simple moving average of $3.49. The stock has a market capitalization of $169.97 million, a PE ratio of -2.94 and a beta of 1.55. Cardiff Oncology, Inc. has a 1 year low of $2.01 and a 1 year high of $5.64.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. On average, analysts expect that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Trading of Cardiff Oncology

Several institutional investors and hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in shares of Cardiff Oncology in the 4th quarter worth $56,000. HighTower Advisors LLC grew its stake in shares of Cardiff Oncology by 123.1% in the 4th quarter. HighTower Advisors LLC now owns 34,213 shares of the company's stock worth $148,000 after buying an additional 18,880 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Cardiff Oncology by 12.8% in the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock worth $234,000 after buying an additional 6,140 shares in the last quarter. Blair William & Co. IL grew its stake in shares of Cardiff Oncology by 14.1% in the 4th quarter. Blair William & Co. IL now owns 282,025 shares of the company's stock worth $1,224,000 after buying an additional 34,947 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Cardiff Oncology by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 982,878 shares of the company's stock worth $4,266,000 after buying an additional 54,646 shares in the last quarter. 16.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CRDF shares. HC Wainwright upped their price objective on shares of Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Jefferies Financial Group started coverage on shares of Cardiff Oncology in a research note on Tuesday, June 24th. They set a "hold" rating and a $3.50 price objective for the company. William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. Finally, LADENBURG THALM/SH SH started coverage on shares of Cardiff Oncology in a research note on Tuesday, July 8th. They issued a "buy" rating and a $19.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Cardiff Oncology currently has an average rating of "Moderate Buy" and a consensus target price of $11.70.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.